SCNI
Scinai Immunotherapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.86
−4.62%Year over year
Reported trailing growth
- Revenue
- +30.2%
- EBITDA
- —
- EBIT
- +0.3%
- EPS
- —
- Free cash flow
- -32.0%
- Operating cash flow
- -30.1%
Forward estimates
Based on analyst estimates
- Revenue
- +44.2%
- EBITDA
- —
- EPS
- +99.7%
Three-year CAGR
- Revenue
- +99.2%
- EBITDA
- +6.6%
- EBIT
- +12.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +4.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026